Literature DB >> 10802692

Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape.

N P Restifo1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10802692      PMCID： PMC1955754          DOI： 10.1038/74955

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  29 in total

1.  Immune response and myoblasts that express Fas ligand.

Authors:  S M Kang; A Hoffmann; D Le; M L Springer; P G Stock; H M Blau
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

2.  Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes.

Authors:  B R Gastman; Y Atarshi; T E Reichert; T Saito; L Balkir; H Rabinowich; T L Whiteside
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

3.  Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction.

Authors:  S M Kang; D B Schneider; Z Lin; D Hanahan; D A Dichek; P G Stock; S Baekkeskov
Journal:  Nat Med       Date:  1997-07       Impact factor: 53.440

4.  Immunology. Ways around rejection.

Authors:  D L Vaux
Journal:  Nature       Date:  1995-10-19       Impact factor: 49.962

5.  A role for CD95 ligand in preventing graft rejection.

Authors:  D Bellgrau; D Gold; H Selawry; J Moore; A Franzusoff; R C Duke
Journal:  Nature       Date:  1995-10-19       Impact factor: 49.962

6.  Gene transfer of Fas ligand induces tumor regression in vivo.

Authors:  H Arai; D Gordon; E G Nabel; G J Nabel
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

7.  Viral inhibition of inflammation: cowpox virus encodes an inhibitor of the interleukin-1 beta converting enzyme.

Authors:  C A Ray; R A Black; S R Kronheim; T A Greenstreet; P R Sleath; G S Salvesen; D J Pickup
Journal:  Cell       Date:  1992-05-15       Impact factor: 41.582

8.  Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock.

Authors:  P Li; H Allen; S Banerjee; S Franklin; L Herzog; C Johnston; J McDowell; M Paskind; L Rodman; J Salfeld
Journal:  Cell       Date:  1995-02-10       Impact factor: 41.582

Review 9.  T cell-tumor cell: a fatal interaction?

Authors:  D B Chappell; N P Restifo
Journal:  Cancer Immunol Immunother       Date:  1998-10       Impact factor: 6.968

10.  Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival.

Authors:  A M Hohlbaum; S Moe; A Marshak-Rothstein
Journal:  J Exp Med       Date:  2000-04-03       Impact factor: 14.307
View more
  56 in total

1.  Countering the 'counterattack' hypothesis.

Authors:  N P Restifo
Journal:  Nat Med       Date:  2001-03       Impact factor: 53.440

2.  Weapons ovarian epithelial tumors may use in immune escape: an immunohistochemical correlational study.

Authors:  Eiman Adel Hasby
Journal:  Pathol Oncol Res       Date:  2011-12-08       Impact factor: 3.201

Review 3.  Cancer vaccines: progress reveals new complexities.

Authors:  Zhiya Yu; Nicholas P Restifo
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

Review 4.  All in the head: obstacles for immune rejection of brain tumours.

Authors:  Paul R Walker; Thomas Calzascia; Pierre-Yves Dietrich
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

Review 5.  Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs.

Authors:  Suphiya Parveen; Sanjeeb K Sahoo
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

6.  Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis.

Authors:  Gianpietro Dotti; Barbara Savoldo; Martin Pule; Karin C Straathof; Ettore Biagi; Eric Yvon; Stephane Vigouroux; Malcolm K Brenner; Cliona M Rooney
Journal:  Blood       Date:  2005-02-15       Impact factor: 22.113

Review 7.  Beyond Cell Death: New Functions for TNF Family Cytokines in Autoimmunity and Tumor Immunotherapy.

Authors:  Fei Yi; Nicholas Frazzette; Anthony C Cruz; Christopher A Klebanoff; Richard M Siegel
Journal:  Trends Mol Med       Date:  2018-06-04       Impact factor: 11.951

Review 8.  The many roles of FAS receptor signaling in the immune system.

Authors:  Andreas Strasser; Philipp J Jost; Shigekazu Nagata
Journal:  Immunity       Date:  2009-02-20       Impact factor: 31.745

9.  Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1.

Authors:  Christopher E Touloukian; Wolfgang W Leitner; Rhonda E Schnur; Paul F Robbins; Yong Li; Scott Southwood; Alessandro Sette; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Immunol       Date:  2003-02-01       Impact factor: 5.422

10.  Fas/Fas ligand mediates keratinocyte death in sunitinib-induced hand-foot skin reaction.

Authors:  Chun-Nan Yeh; Wen-Hung Chung; Shih-Chi Su; Yen-Yang Chen; Chi-Tung Cheng; Yen-Ling Lin; Wan-Chun Chang; Rosaline Chung-Yee Hui; Kun-Chun Chiang; Tsung-Wen Chen; Yi-Yin Jan; Chien-Wei Chen; Ting-Jui Chen; Chih-Hsun Yang; Shuen-Iu Hung
Journal:  J Invest Dermatol       Date:  2014-05-06       Impact factor: 8.551
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.